Skip to content

Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke

Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke: A Multicenter, Randomized, Parallel-controlled Clinical Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04980651
Enrollment
2210
Registered
2021-07-28
Start date
2021-07-01
Completion date
2025-10-01
Last updated
2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Brief summary

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

Detailed description

In this study, 2210 cases of ischemic stroke in 72 hours were included in 10 centers in China according to the principle of random, and parallel control. The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days. The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day for 7 consecutive days. Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning in treating acute ischemic stroke.

Interventions

PROCEDURERemote ischemic conditioning

Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.

PROCEDURESham remote ischemic conditioning

Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.

Sponsors

Yi Yang
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\) Age≥18 years, regardless of sex. * 2\) Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 72 hours of stroke onset. * 3\) Baseline NIHSS ≥ 4, ≤ 24. * 4\) Baseline mRS ≤ 2; * 5\) Signed and dated informed consent is obtained.

Exclusion criteria

* 1\) Patients who undergo thrombolytic therapy or endovascular treatment. * 2\) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture, or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc. * 3\) Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumors,s and other diseases involving the brain. * 4\) Pregnant or lactating women. * 5\) Previous remote ischemic conditioning therapy or similar treatment. * 6\) Severe hepatic and renal dysfunction. * 7\) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons. * 8\) Unwilling to be followed up or treated for poor compliance. * 9\) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission. * 10\) Other conditions that the researchers think are not suitable for the group.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with modified Rankin Scale (mRS) Score 0-2.3 monthsProportion of patients with modified Rankin Scale (mRS) Score 0-2. Ranged from 0 to 6, a low value represents a better outcome.

Secondary

MeasureTime frameDescription
National Institute of Health stroke scale (NIHSS) at 7 days, 30±3 days, 90±3 days from onset.7days, 30±3 days, 90±3 daysNational Institute of Health stroke scale (NIHSS) at 24 hours, 7 days, 30±3 days, 90±3 days from onset. Ranged from 0 to 42, a low value represents a better outcome.
modified Rankin Scale (mRS) Score at 7 days, 30±3 days, 90±3 days from onset.7days, 30±3 days, 90±3 daysmodified Rankin Scale (mRS) at 24 hours, 7 days, 30±3 days, 90±3 days from onset. Ranged from 0 to 6, a low value represents a better outcome.
Barthel Index (BI) at 7 days, 30±3 days, 90±3 days from onset.7days, 30±3 days, 90±3 daysBarthel Index (BI) at 7 days, 30±3 days, 90±3 days from onset. Ranged from 0 to 100, a high value represents a better outcome.
Proportion of patients with hemorrhagic transformation during hospitalization.7 daysProportion of patients with hemorrhagic transformation during hospitalization.
Frequency of adverse events during follow-up.90 daysSevere adverse events through day-90 after the onset of acute ischemic stroke.

Other

MeasureTime frameDescription
Numeric rating scales (NRS) score during intervention.7 daysNumeric rating scales (NRS) score during intervention. Ranged from 0 to 10, a low value represents a less pain.
Proportion of patients with early withdrawal for safety or tolerability reasons.7 daysProportion of patients with early withdrawal for safety or tolerability reasons.
heart rate at 24 hours, 7 days, 30±3 days, 90±3 days.24 hours, 7 days, 30±3 days, 90±3 daysheart rate at 24 hours, 7 days, 30±3 days, 90±3 days.
Blood pressure at 24 hours, 7 days, 30±3 days, 90±3 days.24 hours, 7 days, 30±3 days, 90±3 daysBlood pressure at 24 hours, 7 days, 30±3 days, 90±3 days.

Countries

China

Contacts

Primary ContactYi Yang, MD, PhD
doctor_yangyi@163.com0086-13756661217
Backup ContactZhenni Guo, MD, PhD
zhen1ni2@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026